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ABSTRACT
Objective: The aim of this study was to compare the quality
of life (QOL) of high-risk breast cancer patients included in a
randomized clinical trial (PEGASE 01) comparing conven-
tional chemotherapy versus adding an additional high-dose
chemotherapy (HDC) cycle with blood stem cell support.
Methods: A total of 314 patients were included in the clini-
cal trial. QOL evaluations were available for 199 patients.
QOL was assessed over a 1-year follow-up period, using
the European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire C-30. The results were
analyzed using a linear mixed-effects model.
Results: Toxicity of HDC has a strong negative impact on
patients’ QOL during the treatment phase. This negative
impact tended to last longer in the HDC group, as for most of
the QLQ-C30 scales, the QOL scores of HDC patients tend to
improve at a slower rate than that of patients receiving stan-
dard chemotherapy. In particular, physical functioning
remains deteriorated 1 year after inclusion for HDC patients
comparatively to conventional chemotherapy patients (85.99
vs. 76.65, P = 0.021), and the pain score was still higher in the
HDC group at that time (28.32 vs. 15.97, P = 0.004).
Conclusion: HDC has a negative impact on QOL even after
treatment phase. In the absence of an overall survival beneﬁt
of using HDC for high-risk breast cancer patients, QOL
studies with a longer follow-up play an important role in
informing the complex trade-off implied by HDC between
higher toxicity, reduced risk of relapse, and QOL decrease
after the active phase of treatment.
Keywords: breast cancer, high-dose chemotherapy, quality of
life.
Introduction
The prognosis of breast cancer patients with major
axillary invasion remains poor, despite the progress
related to adjunction of chemotherapy to treatment
combining surgery and radiotherapy. Since the
early diffusion of adjuvant chemotherapy using
anthracycline-containing regimen administered at con-
ventional doses, there has been much debate about the
complex trade-off between the potential, however
limited, gains in terms of survival and the negative
impact on patients’ quality of life (QOL) because of
the toxic side effects involved. These recurrent debates
have increased since high-dose chemotherapy (HDC)
supported by hematopoietic growth factors and
peripheral stem cell transplantation was introduced in
the early 1990s. These “dose-intensive” chemotherapy
regimens have been tested on both advanced and high-
risk breast cancer patients with the hope of increasing
long-term disease-free survival (DFS) [1]. Nevertheless,
to date, only one randomized trial has shown the exist-
ence of any beneﬁts of HDC in terms of overall sur-
vival (OS) [2], while no beneﬁts of this treatment were
observed in other studies [3–8], and a few studies have
suggested that HDC may decrease the risk of relapse
and thus improve DFS [2,9,10].
In addition, HDC is known to be associated with
greater toxicity than standard-dose chemotherapy
regimens. Previous studies have shown that increasing
dose intensity has distinctly detrimental effect on
patients’ QOL [11,12]. These studies suggested that
this negative impact tends to be transient and to dis-
appear soon after the active treatment phase [13,14].
Some of these studies have dealt, however, with HDC
in the context of metastatic breast cancer, and there
is little evidence available so far about the impact
on QOL of adjuvant HDC regimens. The impact of
this treatment may in fact be rather complex: the
decrease in QOL due to the toxic effects of HDC may
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be balanced by future QOL improvements because of
the lower risk of relapse.
In the absence of any evidence of beneﬁts in terms of
OS, the effects of HDC on breast cancer patients have
generally been assumed by the clinical community to
be negative, and HDC has not been adopted as stan-
dard clinical practice. In this context, a better knowl-
edge about the impact of these regimens on QOL
becomes a key parameter for both clinical decision-
making and public health authorities’ decisions about
the diffusion of these innovative treatments.
A QOL study was therefore carried out in the
context of a prospective randomized trial (PEGASE
01) evaluating the clinical impact of adding one HDC
course following standard chemotherapy for high-risk
breast cancer patients. The aim of this study was to
compare the effects on QOL of the two treatment
regimens, during a 1-year follow-up period.
Methods
The PEGASE 01 Clinical Trial
Women eligible for inclusion in the PEGASE 01 trial
had a nonmetastatic breast cancer with more than
seven axillary lymph nodes involved. They had to be
less than 60 years of age with a World Health Orga-
nization performance status 2. Between December
1994 and December 1998, 314 patients at 29 medical
centers were included in the trial. The protocol was
approved by the ethical committee (Consultative Com-
mittee for Protection of Persons Participating in Bio-
medical Research) and all the patients gave their
written informed consent before being included in the
study. All the patients included in the PEGASE 01
protocol were eligible for the QOL study.
After surgery, patients were randomized to receive
four cycles of FEC100 (Epirubicin 100 mg/m2; Cyclo-
phosphamide 500 mg/m2; 5-Fluorouracil 500 mg/m2)
and then, either no further chemotherapy (standard
arm, n = 155) or one additional cycle of HDC (Mitox-
antrone 45 mg/m2 day -6; Cyclophosphamide
60 mg/kg days -5 and -4; and Melphalan 140 mg/m2
day -2; HDC arm, n = 159). In the HDC treatment
arm, peripheral blood stem cells were harvested after
the second and/or third FEC100 cycles under 5 mg/kg
ﬁlgrastim stimulation and reinfused on day 0. Granu-
locyte colony-stimulating factor (G-CSF) (5 mg/kg/day)
began on day 1 after stem cell transplantation and was
given until the absolute neutrophil count > 1 ¥ 109/L
for three consecutive days.
After chemotherapy, radiotherapy was undergone
by the women in both treatment groups and positive
hormonal receptor menopausal women were given
tamoxifen for 3 years.
The primary end point deﬁned in the clinical pro-
tocol was DFS. QOL and economic outcomes [15]
were secondary end points.
Assessment of QOL
Quality of life was assessed using the self-administered
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire C-30 (EORTC
QLQ-C30). This questionnaire, which was speciﬁcally
designed for cancer patients [16], has been validated
for international use and its psychometric properties
for breast cancer patients have been reported [17]. It
contains 30 items subdivided into ﬁve functioning
scales (physical, role, emotional, cognitive and social
functioning), three symptom scales (fatigue, nausea/
vomiting, pain), and six single items (dyspnea, sleep
disturbance, loss of appetite, constipation, diarrhea,
and ﬁnancial difﬁculties).
Patients’ answers to the EORTC QLQ-C30 were
scored using the algorithms supplied by the EORTC
[18]. All scores range from 0 to 100, where a higher
score corresponds to a higher functional level or a
higher level of symptoms.
Timing of the Assessment
The number of questionnaires administered during
follow-up period was chosen to minimize the burden
on the patients. Consequently, the EORTC QLQ-C30
was administered ﬁve times: 1) on the ﬁrst day of the
last cycle of FEC100; 2) at the end of radiotherapy for
standard arm patients and after blood stem cell trans-
plantation for HDC patients; 3) 1 month after radio-
therapy for standard arm patients and at the end of
radiotherapy for HDC patients; 4) 3 months after
radiotherapy for both arms; and 5) 1 year after inclu-
sion for both arms. FEC-related side effects were
assessed at the last FEC cycle for both arms. HDC-
related side effects were measured at discharge from
transplantation unit for HDC patients. In addition,
patients’ sociodemographic characteristics were re-
corded at inclusion.
Patient’s compliance in completion of question-
naires was deﬁned as the ratio between the number of
completed questionnaires returned and those expected.
The expected number of questionnaires was the total
number which should have been completed by each
patient according to the protocol, depending on how
long they survived.
Statistical Analysis
Particularly close attention was devoted to the prob-
lems that may be related to missing data in the QOL
study. Standard statistical analysis of repeated mea-
sures usually considers that the probability that some
data are missing is independent of the value of these
data. According to the classiﬁcation developed by
Rubin [19], such data should be considered as Missing
Completely At Random (MCAR) and classical analysis
of variance remains appropriate for statistical analysis
in this case. MCAR data should, however, be distin-
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guished from missing-at-random (MAR) data. In the
latter case, which is more likely to happen in the
context of longitudinal assessment of QOL embedded
in a clinical trial, the probability some data are missing
may depend on the previous (observed) values of the
data, but does not depend on the speciﬁc value of the
missing data.
Missing data are indeed very rarely MCAR in
cancer clinical trials, and statistical methods based on
the assumption that data are rather MAR are prefer-
able for analysis [20]. The approach we used therefore
assumed that the missing data mechanism was MAR,
and analysis was performed using a linear mixed-
effects model, unbiased under the MAR assumption
[21,22]. The general form of the model is Yi = Xib
+ Zigi + ei where Yi is the QOL vector for ith individual,
Xi the matrix of ﬁxed effects (i.e., the covariates), and
Zi the matrix of random effects. The intrasubject cor-
relations (repeated measures) are modeled with inclu-
sion of random effects in the model.
Our model included an intercept and a slope as
random effects. This means that the baseline value of
the scores, as well as their evolution in time, may differ
between patients. Time was ﬁtted in the model as a
continuous variable, because the timing of the assess-
ments varied across patients.
In order to account for the decrease in QOL
observed at the second assessment (Q2) for HDC
patients (due to the intensiﬁcation phase), we included
in the model an indicator variable for the second
assessment (EvalQ2 = 1 if it was the second assess-
ment, and 0 otherwise) as in the study by Jacqmin-
Gadda et al. [23]. This additional variable allowed us
to model the change in the slope after the second QOL
assessment.
Our model can therefore be written as follows:
Y Arm Time Arm Time
EvalQ EvalQ A
ij i ij i ij= + + + ×( ) +
+ ×
β β β β
γ γ
0 1 2 3
1 22 2 rm
Time
i i
i ij ij
( ) + +
+
ν
ν ε
0
1
It was estimated using the SAS Proc Mixed procedure
[24].
Results
Clinical Results
The baseline data on the 314 patients included in the
clinical protocol, such as age, stage, number of positive
lymph nodes, hormonal status, estrogen and progest-
erone receptor, and histological types, were well bal-
anced between the two treatment arms.
Patients’ main clinical characteristics and survival
time are summarized in Table 1. After a median
follow-up period of 61.2 months, a signiﬁcant differ-
ence in DFS was observed, with mean DFS durations
Table 1 Clinical characteristics and outcomes for patients included in the PEGASE 01 trial
All PEGASE 01 patients Patients in the QOL study
Standard group
(n = 155)
HDC group
(n = 159)
Standard group
(n = 99)
HDC group
(n = 100)
Age (year), median (range) 47 (29–60) 48 (25–59) 47 (27–49) 47 (25–59)
Breast conserving surgery (%) 60 (39) 75 (47) 38 (38) 50 (50)
Tumor classiﬁcation (%)
T0 5 (3) 2 (1) 2 (2) 2 (2)
T1 42 (27) 43 (27) 24 (24) 29 (29)
T2 70 (45) 91 (57) 49 (49) 53 (53)
T3–4 28 (18) 20 (13) 20 (20) 16 (16)
Undetermined 10 (6) 3 (2) 4 (4) 0 (0)
Histological grade SBR
I 8 (5) 15 (9) 7 (7) 11 (11)
II 70 (45) 50 (31) 41 (41) 29 (29)
III 64 (41) 82 (52) 45 (45) 53 (53)
Unknown 13 (8) 12 (8) 6 (6) 7 (7)
Positive nodes
Median (range) 13 (8–36) 11 (8–36) 13 (8–34) 12 (8–26)
Receptor status
ER positive 91 (59) 105 (66) 57 (57) 70 (70)
PR positive 87 (56) 86 (54) 60 (60) 54 (54)
Hormonal status (%)
Premenopausal 108 (70) 109 (69) 70 (71) 68 (68)
Postmenauposal 47 (30) 50 (31) 29 (29) 32 (32)
Toxicity duration (month)*
Mean (SD) 5.24 (0.07) 6.88 (0.09) 5.21 (0.74) 7.03 (0.81)
Overall survival
Mean duration 70.27 71.78 69.30 72.15
5-year rate (%) 67.8 73.7 68.0 75.0
Disease-free survival
Mean duration 49.5 61.1 48.9 64.1
5-year rate (%) 40.7 60.0 41.0 61.9
*Toxicity was calculated as the total duration of treatment, until the end of radiotherapy.
ER,estrogen receptor; HDC, high-dose chemotherapy; PR, progesterone receptor; QOL, quality of life; SBR, Scarff Bloom Richardson; SD, standard deviation.
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(95% conﬁdence interval [CI]) of 49.5 months (CI
44.1–54.8) and 61.1 months (CI 56.1–65.8) in
standard treatment arm and HDC arm, respectively
(P < 0.001). The 5-year DFS rates were 40.7% and
60% (65 relapses occurred in the standard treatment
arm vs. 44 in the HDC arm), respectively.
Nevertheless, OS was the same in both treatment
groups with mean durations of 70.3 months (CI 65.5–
75.1) in standard arm and 71.8 months (CI 67.8–75.7)
in HDC arm. The 5-year OS rates were 67.8% and
73.7% in the standard and HDC arms, respectively.
Recruitment and Participation in the QOL Study
Among the 314 patients included in the PEGASE 01
trial, 50 patients could not be included in the QOL
study for the following reasons: three centers refused
to participate in the QOL study (41 patients); ques-
tionnaires could not be administered to seven patients
who were treated outside the participating center; two
patients were illiterate and could not complete ques-
tionnaires. In addition, 65 patients expressly refused to
participate in the QOL study.
We present the QOL results on the 199 patients
who completed at least one QOL questionnaire (99 in
the standard group and 100 in the HDC group). Char-
acteristics of these patients are given in Table 1. There
were no statistically signiﬁcant differences in terms
of the main clinical characteristics between the 199
patients included in the QOL study and the 115
patients not included in the study.
The response rate of the 199 participating patients
to QOL questionnaires was good: it amounted to 90%
during the active phase of treatment and 76% during
the ﬁrst year of follow-up. There was no statistically
signiﬁcant difference in the compliance rates between
the two treatment arms (88% and 73% in the standard
treatment arm vs. 91% and 79% in the HDC arm).
Nevertheless, it is worth noting that 48% of the
respondents answered all ﬁve questionnaires, whereas
52% did not answer at least one of the questionnaires
during the study period.
Sociodemographic Characteristics
The 199 patients included in our analysis had the
following sociodemographic characteristics (HDC arm
vs. standard arm): 1) the great majority of the patients
were married (77% vs. 66%) and had at least one child
(81% in both arms); 2) more than half of these patients
were not secondary school or university graduates
(55% vs. 62%), but the great majority had a profes-
sional activity before incurring the disease (68% vs.
61%). No statistically signiﬁcant differences were
observed between the sociodemographic characteris-
tics of the two groups of patients.
QOL Results
The mean EORTC QLQ-C30 scores obtained on the
global QOL scale, the ﬁve functional and the three
symptom scales during the ﬁrst year after inclusion, as
estimated with the mixed-effects model, are presented
in Table 2 and illustrated in Figure 1.
Table 2 Estimation of mean EORTC QLQ-C30 scores for nine QOL scales using a mixed-effects model
Arm
Assessment time*
Q1 Q2 Q3 Q4 Q5
Mean SD Mean SD Mean SD Mean SD Mean SD
Global QOL Standard 60.19 1.76 60.62 2.11 63.71 1.56 66.05 1.63 71.92 2.35
HDC 59.13 1.77 35.61 1.99 61.84 1.54 63.88 1.73 65.91 2.14
Functioning scales†
Physical Standard 77.78 2.16 79.39 2.48 80.25 1.83 81.89 1.77 85.99 2.20
HDC 76.42 2.18 48.53 2.39 76.51 1.76 76.58 1.73 76.65 1.98
Role Standard 53.27 3.20 54.46 4.00 60.05 2.71 64.58 2.78 75.89 4.14
HDC 53.95 3.30 24.21 3.79 56.84 2.66 59.00 2.95 61.17 3.75
Cognitive Standard 73.02 2.48 73.21 2.84 74.94 2.23 76.22 2.24 79.42 2.82
HDC 72.55 2.50 51.94 2.70 73.87 2.18 74.87 2.26 75.86 2.59
Emotional Standard 69.54 2.27 70.03 2.66 70.29 2.02 70.79 2.05 72.04 2.73
HDC 66.53 2.30 59.20 2.51 67.79 1.98 68.73 2.10 69.67 2.49
Social Standard 74.08 2.64 76.24 3.08 76.36 2.33 77.89 2.34 81.70 3.04
HDC 65.03 2.70 36.81 2.98 68.70 2.28 71.45 2.35 74.20 2.73
Symptom scales‡
Fatigue Standard 48.26 2.33 46.69 2.84 41.76 2.07 37.43 2.12 26.60 2.91
HDC 50.64 2.37 80.90 2.64 44.91 2.04 40.62 2.19 36.32 2.64
Nausea/vomiting Standard 18.94 2.40 11.07 2.92 13.16 1.74 9.31 1.50 0.32 1.99
HDC 23.27 2.48 61.09 2.75 15.50 1.57 9.67 1.30 3.85 1.60
Pain Standard 21.94 2.43 22.43 3.00 20.15 2.12 18.96 2.16 15.97 3.03
HDC 21.07 2.49 47.14 2.88 23.97 2.08 26.14 2.22 28.32 2.70
*Q1: end of FEC100;Q2: end of radiotherapy for standard arm and post-transplantation for HDC arm;Q3: 1 month post radiotherapy for standard arm and end of radiotherapy
for HDC arm; Q4: 3 months post radiotherapy; Q5: 1 year post inclusion.
†Higher score indicates better function.
‡Higher score indicates more symptoms.
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30; HDC, high-dose chemotherapy; QOL, quality of life; SD,
standard deviation.
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Table 2 and Figure 1 suggest that QOL increased in
all the patients, but that this improvement was not
identical through time between both arms. For HDC
patients, as shown in Table 2, all the functioning scales
were drastically deteriorated and physical, role, cogni-
tive, social, and global QOL scores reached very low
values just after the end of intensive chemotherapy (Q2
in the protocol). In addition, the fatigue, nausea, and
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Figure 1 Evolution in time of six major scores of the Quality of Life Questionnaire C-30, according to treatment group. HDC, high-dose chemotherapy;
QOL, quality of life.
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pain scores increased considerably during this active
phase of treatment, which suggest that these side
effects of the treatment greatly affected the patients’
QOL. Although HDC patients’ scores remained
unchanged during the ﬁrst year, QOL gradually
increased in the standard treatment group. In particu-
lar, the physical score remained practically the same
at Q3, Q4, and Q5 assessments in HDC patients,
but increased from 80.3 to 86.0 in standard group
patients. One year after inclusion, large differences
existed between the two arms for some major scores,
such as physical functioning, role functioning, fatigue,
and pain. In addition, during the last few months of
follow-up, QOL continued to improve in the case of
standard treatment patients, but remained stable in
that of HDC patients.
The Impact of HDC on QOL during the Active
Phase of Treatment
The mixed-effects model was used ﬁrst to quantify the
impact of HDC on QOL immediately after the end of
HDC (the Q2 questionnaire). This impact is given by
the parameter g2 in Table 3. For all the scores, the
interaction between the variables Arm (HDC arm) and
EvalQ2 (assessment at Q2) was found to be highly
signiﬁcant. This conﬁrms what was already suggested
by Table 2 and Figure 1: the QOL of patients who
received HDC was considerably deteriorated during
the active phase of treatment.
Longitudinal Analysis:The Effects of
Treatment Arm and Time
The mixed-effects model was also used to rigorously
estimate the respective roles of time, treatment arm,
and their interaction in the evolution of QOL. Table 4
presents the estimated values of each parameter and
their level of signiﬁcance.
Quite logically, both groups had similar QOL
scores at baseline, showing no signiﬁcant differences
on any of the scales (P > 0.05 parameter b1). There was
one exception, however, in the case of the social score,
which was lower in the HDC group than in the other
group (65.03 vs. 74.08; P = 0.017).
The model also conﬁrms the existence of a positive
trend with time in all patients: the global QOL score
and all the functional scores increased signiﬁcantly
(b2 > 0), with the one exception of the “emotional”
score, which was not found to differ between the two
groups. Table 4 also shows that all three symptom
scores decreased with time (b2 < 0), although this
decrease was not statistically signiﬁcant in the case of
the “pain” scale.
Analyzing the interaction between time and arm
given by the parameter b3 made it possible to differen-
tiate the evolution of QOL in the two treatment arms.
The negative values of the b3 parameter for global
QOL as well as three of the functioning scales indicate
that these scores increased at a lower rate in HDC
patients than in standard arm patients. Although this
Table 3 Effect of the high-dose chemotherapy course* on
QLQ-C30 scores
EORTC scales
Variable in the model EvalQ2 ¥ Arm
Estimate g2† P-value
Global QOL -22.28 <0.0001
Physical -27.87 <0.0001
Role -27.14 <0.0001
Cognitive -19.85 <0.0001
Emotional -7.63 0.016
Social -29.77 <0.0001
Fatigue 28.89 <0.0001
Nausea/vomiting 43.79 <0.0001
Pain 23.67 <0.0001
*Second QOL assessment (Q2 in the protocol).
†The value of the estimated parameter indicates the average change in the score
during HDC: a positive value indicates an increase of the score; a negative value
indicates a decrease of the score.
EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30,
Quality of Life Questionnaire C-30; QOL, quality of life.
Table 4 Longitudinal analysis: effect of time and treatment on the EORTC scores
EORTC scales
Variable entered in the model
b1
Baseline arm effect
b2
Time
b3
Time ¥ Arm
Estimate P-value Estimate P-value Estimate P-value
Global QOL -1.06 0.67 1.17 <0.0001 -0.49 0.16
Functional scales*
Physical -1.36 0.66 0.82 0.0015 -0.80 0.021
Role 0.69 0.88 2.26 <0.0001 -1.54 0.022
Cognitive -0.47 0.89 0.64 0.0267 -0.31 0.43
Emotional -3.01 0.35 0.25 0.39 0.06 0.87
Social -9.05 0.017 0.76 0.019 0.15 0.73
Symptom scales†
Fatigue 2.37 0.48 -2.17 <0.0001 0.73 0.08
Nausea/vomiting 4.32 0.21 -1.93 <0.0001 -0.01 0.97
Pain -0.88 0.80 -0.60 0.08 1.32 0.004
*A positive estimate indicates that the mean score increases when the value of the variable rises, indicating an improvement in QOL.A negative estimate indicates that the mean
score decreases when the value of the variable rises, indicating a decrease in QOL.
†A positive estimate indicates that the mean score increases when the value of the variable rises, indicating a negative impact on QOL.A negative estimate indicates that the mean
score decreases when the value of the variable rises, indicating a postive impact on QOL.
EORTC, European Organization for Research and Treatment of Cancer; QOL, quality of life.
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difference was not signiﬁcant for global QOL, it
reached signiﬁcance level in the case of two important
functional scales: physical (P = 0.021) and role (P =
0.022). The positive values of the pain and fatigue
scores show that these two symptoms decreased at a
lower rate in the HDC arm: this difference was clearly
signiﬁcant in the case of pain (P = 0.004), but not
fatigue (P = 0.08).
Conclusion
High-dose chemotherapy is known to decrease QOL
during a relatively short period of time because of the
side effects commonly associated with cytotoxic
drugs. As to date only one randomized trial has been
able to demonstrate that HDC offers a beneﬁt in
terms of OS [2], and even if we can hope it will
reduce the risk of relapse, toxicity may jeopardize the
use of these innovative treatments. In this context,
the impact of HDC on QOL becomes a central
parameter on which to base medical decision-making,
but very little is known about this impact as very few
studies of adjuvant HDC with autologous blood stem
cell transplantation have included QOL assessment
[25–28].
The aim of this study was to assess the impact of
HDC on the QOL of breast cancer patients with
axillary lymph node invasion during a 12-month
period. Using a mixed effects model, the QOL of
patients receiving HDC was compared to that of
patients who received standard-dose chemotherapy.
The results of our study showed that the toxicity of
HDC has a strong negative impact on patients’ QOL
during the active phase of treatment. In addition, this
negative impact on patients’ QOL tends to last longer
than for patients treated with standard chemo-
therapy. The parameter reﬂecting the interactions
between time and treatment group (b3) was signiﬁ-
cant or at borderline signiﬁcance level for some
major QOL scales, showing that the pattern of QOL
in time differed between treatment groups. In particu-
lar, physical functioning was obviously still deterio-
rated 1 year after inclusion in HDC patients, and
the negative impact of pain (and possibly fatigue)
remains more important for them. Our results show
that the QOL of HDC patients tends to improve at a
slower rate than that of patients treated with stan-
dard chemotherapy, at least during the ﬁrst year after
the start of treatment. Therefore, gains in QOL due
to the decreased risk of relapse may indeed be lower
than they were previously thought to be. Interest-
ingly, the emotional score did not increase signiﬁ-
cantly during the 1-year follow-up period, and did
not differ between treatment groups. The most deci-
sive factor here therefore seems to be the disease
status, and not the type of treatment undergone.
The results of this study are interesting as those
of previous QOL studies suggested that the negative
impact of adjuvant chemotherapy does not affect the
acceptability of this treatment [11,13,29–31]. In the
speciﬁc context of adjuvant HDC, the authors of pre-
vious studies concluded that more intensive therapies
were associated with a decrease in QOL because of the
side effects occurring during the treatment period, but
that this decrease was transient and tended to disap-
pear quite soon after treatment was completed
[14,27,28]. In a study by Peters et al., however, breast
cancer patients treated with HDC with autologous
transplantation reported having a number of problems
such as sleep disturbance, anxiety, and fatigue 1 year
after the end of treatment, but did not suffer from any
major decrease in their QOL [32].
One possible reason for the differences between
the results of this study and previous ones may have
to do with the methods used. Standard statistical
methods for repeated measures require complete
data, and the statistical analysis is therefore restricted
to those patients who answered all the QOL ques-
tionnaires during the study period. In situations
where data were missing because of the disease or its
treatment, this approach may introduce signiﬁcant
biases into the statistical analysis. This is particularly
true in the case of patients in the advanced stages of
the disease: if their disease prevents patients from
answering QOL questionnaires, including only those
patients who completed all the QOL questionnaires
might lead to overestimating QOL [33]. The mixed-
effects model used here was based on the assumption
that missing data are MAR, which is highly plausible
in the case of our data. This approach has been used
in previous research on cancer patients to analyze
longitudinal QOL data [34–37], but to our knowl-
edge, this is the ﬁrst study in which this approach has
been used to assess how HDC affects QOL in breast
cancer patients. It is always difﬁcult to choose the
most appropriate method for dealing with missing
QOL data in longitudinal follow-up studies, and this
topic has recently been studied by several authors
[38–41]. In particular, analyzing QOL during a
longer follow-up period may require the use of other
types of models.
The clinical signiﬁcance of differences in QOL is an
important point which has to be discussed in QOL
studies. It was recently concluded that all the methods
designed to assess what might be called a meaningful
difference in QOL scores lead to the same conclusion
[42]. A difference of 5 to 10 points in patients’ scores
on a 0–100-point scale is generally considered to be
meaningful [43], and that was the criterion adopted
here. The large statistical difference in the QOL scores
observed in this study between groups therefore seems
to reﬂect a clinically signiﬁcant difference which was
perceivable by the patients.
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Study Limitations
One of the main limitations of this study, as in other
studies carried out alongside clinical trials, is that we
cannot completely exclude the possibility that some
bias may have occurred in our QOL assessments,
because a proportion of the patients participating in
the clinical trial could not be included in the QOL
study itself. Nevertheless, no differences were found to
exist between the socioeconomic and clinical charac-
teristics of the PEGASE 01 patients who were included
in the QOL study and those who were not. In addition,
the use of a mixed-effects model allowed us to take
into account in the statistical analysis all the informa-
tion available on each of the 199 patients who partici-
pated in the QOL study.
Another limitation of this study is the short duration
of the follow-up period (1 year), as side effects may
occur in the long term and not be limited to the ﬁrst few
months after the treatment phase. It has in fact been
reported in studies on bone marrow transplantation
[44] that some side effects may not be properly assessed
within a single year of follow-up. In particular, some
debate is focusing today on questions about cognitive
function [45,46]. Long-term QOL is of considerable
importance, as it contributes decisively to the overall
value of intensiﬁed regimens. As the ultimate goal of
adjuvant treatment is to improve long-term survival,
short-term toxicity should be readily accepted in situa-
tions where a therapeutic beneﬁt is observed in terms of
OS. Of course, in cases where the OS beneﬁts are not
very clear, it can be argued that DFS should be used as
a surrogate criterion because a relapse of cancer is a
traumatic event which can have serious psychological
consequences [47–49]. This implies, however, that
delaying relapses translates into a better QOL for
patients as long as they remain disease-free. The results
of the PEGASE 01 protocol suggest that in the case of
HDC for high-risk breast cancer patients, such assump-
tion should be handled with caution: HDC patients
undergo a longer active phase of treatment, which is
associated with signiﬁcantly higher toxicity, whereas
the mean time elapsing before a relapse occurs is longer
than for standard arm patients. The extent to which
delays in relapses actually compensate for the higher
toxicity to which patients are exposed during their
treatment depends strongly on the level of patients’
QOL during the remission period.
No comorbidity data were available in this study, as
our study population consisted of fairly young women
(<60 years of age). Nevertheless, changes in comorbid-
ity may have a signiﬁcant effect on QOL in the long
term, and this point should therefore be included in
future studies evaluating HDC for breast cancer
patients.
In conclusion, the gains in QOL obtained by delay-
ing relapse with HDC should be balanced with the
losses incurred by HDC patients not only during the
active phase of treatment but afterward. Future QOL
studies should be carried out during longer follow-up
period to clarify the difﬁcult trade-off which arises
with HDC between greater toxicity, the lower risk of
relapse and the persistent decrease in QOL even after
the active phase of treatment.
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